MARKET

AZN

AZN

Astrazeneca Plc
NASDAQ
67.93
+1.33
+2.00%
Opening 09:44 01/21 EST
OPEN
67.75
PREV CLOSE
66.60
HIGH
67.93
LOW
67.59
VOLUME
360.26K
TURNOVER
--
52 WEEK HIGH
87.68
52 WEEK LOW
59.19
MARKET CAP
210.66B
P/E (TTM)
32.67
1D
5D
1M
3M
1Y
5Y
1D
AstraZeneca overhauling management at China division, FT reports
TipRanks · 10m ago
AstraZeneca’s Datroway Approved for Advanced Breast Cancer in the US
TipRanks · 2h ago
Artisan International Fund Q4 2024 Commentary
Seeking Alpha · 3h ago
AstraZeneca (AZN) Gets a Buy from Goldman Sachs
TipRanks · 7h ago
Reported Friday, FDA Approves Daiichi Sankyo And AstraZeneca's DATROWAY AS A New Treatment Option For HR Positive, HER2 Negative Breast Cancer In The U.S.
Benzinga · 8h ago
Up 1,000% in 2024, Wall Street Believes This Growth Stock Can Still Skyrocket
Barchart · 8h ago
Investors who lost money on AstraZeneca PLC(AZN) should contact Levi & Korsinsky about pending Class Action - AZN
Barchart · 10h ago
AstraZeneca Secures FDA Nod for New ADC Drug Datroway in Breast Cancer
NASDAQ · 19h ago
More
About AZN
AstraZeneca PLC is a science-led biopharmaceutical company. It discovers, develops, and commercializes prescription medicines in oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal and metabolism, respiratory and immunology and vaccines and immune therapies. Its key marketed oncology products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Zoladex, Faslodex and others. Its rare diseases products include Soliris, Ultomiris, Strensiq and Kanuma. Its biopharmaceuticals products include Farxiga, Crestor, Breztri and others. Its investigational vaccine candidate IVX-A12, which targets both respiratory syncytial virus and human metapneumovirus. Its oncology candidate includes FPI-2265 targeting prostate specific membrane antigen for metastatic castration resistant prostate cancer, which is in a Phase II trial. It also discovers, develops, and manufactures T-cell receptor therapies. Its Eneboparatide is an investigational therapeutic peptide.

Webull offers AstraZeneca PLC (ADR) stock information, including NASDAQ: AZN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AZN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AZN stock methods without spending real money on the virtual paper trading platform.